BioCentury | Sep 19, 2016
Company News

GlaxoSmithKline, Aspen deal

...the partners’ 2013 deal. Aspen will now have worldwide rights to marketed injectable anticoagulants Fraxiparine nadroparin...
BioCentury | Oct 7, 2013
Company News

Aspen, GlaxoSmithKline, Merck sales and marketing update

...GlaxoSmithKline said it agreed to sell its injectable anticoagulants Fraxiparine nadroparin and Arixtra fondaparinux and the...
...million ($269.3 million). GSK has rights to the products from Sanofi (Euronext:SAN; NYSE:SNY, Paris, France). Fraxiparine...
BioCentury | Jul 29, 2013
Company News

Aspen, GlaxoSmithKline deal

...2Q13 earnings that branded and generic drug supplier Aspen offered to acquire injectable anticoagulants Fraxiparine nadroparin...
...to the products. GSK has rights to the products from Sanofi (Euronext:SAN; NYSE:SNY, Paris, France). Fraxiparine...
...inhibitor. For the six months ended June 30, GSK reported £113 million ($171.9 million) in Fraxiparine...
BioCentury | Jul 15, 2013
Company News

Aspen, Merck deal

...APIs manufactured at the site is heparin , which is used in the manufacture of Fraxiparine...
...LSE:GSK; NYSE:GSK, London, U.K.) worldwide rights, except for China, Pakistan and India, to injectable anticoagulants Fraxiparine...
BioCentury | Dec 14, 2009
Clinical News

Fraxiparine nadroparin: Post-marketing study data

...miscarriages by the 20th week of pregnancy showed that aspirin alone or in combination with Fraxiparine...
...Society of Hematology meeting in New Orleans. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Fraxiparine nadroparin...
BioCentury | Dec 15, 2008
Clinical News

Nadroparin cardiovascular data

...In the double-blind PROTECHT study in 1,166 cancer patients, once-daily subcutaneous nadroparin met the primary endpoint...
...San Francisco. GlaxoSmithKline markets nadroparin as Fraxiparine . GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Product: Nadroparin...
BioCentury | Apr 19, 2004
Company News

GlaxoSmithKline, Sanofi-Synthelabo SA deal

...GSK will pay E453 million ($547.7 million) in cash for global rights to SAN's Fraxiparine nadroparine...
...Bondeville, France, and will be responsible for ongoing trials for Arixtra. In 2003, sales of Fraxiparine...
BioCentury | Apr 13, 2004
Company News

GSK, Sanofi anti-coagulant deal

...million ($547.7 million) in cash to Sanofi - Synthelabo (Euronext:SAN; SNY) for global rights to Fraxiparine...
...Bondeville, France, and will be responsible for ongoing trials for Arixtra. In 2003, sales of Fraxiparine...
Items per page:
1 - 8 of 8